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MaBACKGROUND Long noncoding ribonucleic acids (lncRNAs) are a subclass of regulatory noncoding ribonucleic acids for
which expression and function in human endothelial cells and angiogenic processes is not well studied.
OBJECTIVES The authors discovered hypoxia-sensitive human lncRNAs via next-generation ribonucleic acid
sequencing and microarray approaches. To address their functional importance in angiogenic processes, several endo-
thelial lncRNAs were characterized for their angiogenic characteristics in vitro and ex vivo.
METHODS Ribonucleic acid sequencing and microarray-derived data showed speciﬁc endothelial lncRNA expression
changes after hypoxia. Validation experiments conﬁrmed strong hypoxia-dependent activation of 2 intergenic lncRNAs:
LINC00323 and MIR503HG.
RESULTS Silencing of these lncRNA transcripts led to angiogenic defects, including repression of growth factor
signaling and/or the key endothelial transcription factor GATA2. Endothelial loss of these hypoxia-driven lncRNAs
impaired cell-cycle control and inhibited capillary formation. The potential clinical importance of these endothelial
lncRNAs to vascular structural integrity was demonstrated in an ex vivo model of human induced pluripotent stem
cell–based engineered heart tissue.
CONCLUSIONS The authors report an expression atlas of human hypoxia-sensitive lncRNAs and identiﬁed 2 lncRNAs
with important functions to sustain endothelial cell biology. LncRNAs hold great promise to serve as important future
therapeutic targets of cardiovascular disease. (J Am Coll Cardiol 2015;66:2005–15) © 2015 by the American College of
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ABBR EV I A T I ON S
AND ACRONYMS
EC = endothelial cell
EHT = engineered heart tissue
GFP = green ﬂuorescent
protein
HIF1a = hypoxia-inducible
factor 1a
HUVEC = human umbilical vein
endothelial cell
lincRNA = long intergenic
noncoding ribonucleic acid
lncRNA = long noncoding
ribonucleic acid
miR = mature micro–
ribonucleic acid
miRNA = micro–ribonucleic
acid
mRNA = messenger ribonucleic
acid
RNA = ribonucleic acid
RNA-seq = ribonucleic acid
sequencing
siRNA = small interfering
ribonucleic acid
VEGF = vascular endothelial
growth factor
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2006pathophysiology and serve as interesting
treatment targets (1,2). Of importance, miRs
are already used in diagnostic as well as
therapeutic approaches (3,4). Recently, the
more heterogeneous RNA subclass of long
noncoding RNAs (lncRNAs) has become the
focus of intense research. LncRNAs are
deﬁned as non-protein-coding RNAs >200
nucleotides in length. Their genomic locali-
zation can either be in sense or antisense to
coding genes or intergenic (5,6).SEE PAGE 2016The current annotation of lncRNAs within
databases is a very dynamic process because
of actively increasing knowledge in this ﬁeld
(7). In contrast to miRNAs, whose functional
relevance is due mainly to targeting of partial
complementary messenger RNA (mRNA),
lncRNA-based mechanisms are more diverse
and also dependent on their localization
within the nuclear or cytosolic compartment
(8,9). In vivo, loss-of-function analysis has
revealed the crucial importance of certain
lncRNAs during cardiac wall and cardiac
lineage development (10,11). An MYH7-encoded lncRNA, Myhrt, was identiﬁed to regulate
cardiac function and be a valuable therapeutic target
to counteract cardiac hypertrophy (12). Expression of
function of some other lncRNAs in the vasculature
has been described before; for instance, the control
of endothelial cell (EC) homeostasis and junction
contacts was demonstrated to be dependent on
antagonism of Tie-1 mRNA via Tie-1 antisense lncRNA
in vivo (13). In line, Tie1 antisense lncRNA was in-
creased in patients with vascular anomalies, in-
dicating therapeutic potential. Another antisense
lncRNA, SENCR, was identiﬁed in human artery
smooth muscle cells using RNA sequencing (RNA-seq)
(14). SENCR knockdown triggered a cascade of anti-
migratory events in this type of vascular cell.
Very recently, endothelial lncRNA MIAT was found
to be induced in diabetic conditions (15). Therapeutic
intervention with MIAT improved microvascular
dysfunction in a diabetic disease model in vivo via
interference with binding of MIAT toward vascular
endothelial growth factor (VEGF) and miR-150-5p.
The endothelial-enriched lncRNA MALAT1 was also
shown to control the migration and sprouting of ECs
(16). However, none of the aforementioned lncRNAs
was speciﬁcally investigated in the setting of endo-
thelial hypoxia.
LncRNAs may also enter the circulation to form a
basis for new diagnostic and prognostic strategicapproaches to cardiovascular disease (17,18). Hypoxia
is a major trigger of angiogenic events in ECs (19). In
strong contrast to miRNAs, current knowledge about
the expression and function of lncRNAs in human ECs
is nascent. A direct long intergenic noncoding RNA
(lincRNA)–p21 mediated mechanism of hypoxia-
inducible factor 1a (HIF1a) stabilization and a poten-
tial role in angiogenic events has been demonstrated
but, so far, in cancer cells only (20).
In this work, we globally studied whether lncRNAs
are differentially regulated in human ECs through
hypoxia using RNA-seq and microarray approaches
and applied gain- and loss-of-function studies for
selected novel endothelial lncRNAs in vitro and
ex vivo to study their functional importance for
endothelial biology. Thus, the aim of this study was
to provide an overview of hypoxia-sensitive func-
tional lncRNAs to discover new entry points for the
development of lncRNA-based strategies to modulate
tissue vascularization.
METHODS
We used 2 mg of total RNA from human umbilical vein
ECs (HUVECs) cultured under normoxic or hypoxic
conditions for 24 h and subjected to RNA-seq analysis
(n ¼ 3). After extracting the total RNA from the sam-
ples, ribosomal RNA was removed from the total RNA.
By using the fragmentation buffer, the left RNA was
fragmented into short fragments, then the ﬁrst strand
complementary deoxyribonucleic acid was synthe-
sized by random hexamer-primer using the left RNA
fragments as templates. Buffer, nucleotide tri-
phosphates containing deoxyribose, ribonuclease H,
and deoxyribonucleic acid polymerase I were added
to synthesize the second strand. The double-strand
complementary deoxyribonucleic acid was puriﬁed
using the QiaQuick polymerase chain reaction
extraction kit (Qiagen, Venlo, the Netherlands) and
washed with elution buffer for end repair and poly(A)
addition. Finally, sequencing adaptors were ligated to
the fragments, which were puriﬁed by agarose gel
electrophoresis and enriched by polymerase chain
reaction ampliﬁcation. The library products were
sequenced using the HiSeq 2000 (Illumina, San Diego,
California).
A detailed methods section is available in the
Online Appendix.
RESULTS
SIGNATURE OF ENDOTHELIAL lncRNA EXPRESSION
DURING HYPOXIA. To identify hypoxia-sensitive
endothelial lncRNAs, HUVECs were ﬁrst subjected
to 24 h of hypoxia. In preliminary experiments,
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2007we found this time point optimal for identifying
regulations of a vast majority of lncRNAs (data not
shown). Hypoxia-sensitive noncoding RNA expres-
sion was detected via 2 approaches, microarray- and
RNA-seq-based techniques. We ﬁrst focused on the
microarray-derived noncoding RNA dataset to
search for lncRNAs using the following criteria:
minimal 4-fold deregulation and intergenic lncRNA
localization. By this approach, we identiﬁed
LINC00323 (lnc-DSCAM-1) to be the strongest (w8-
fold) up-regulated lincRNA after hypoxia (probe
uc002yyv) (Online Table 1).
RNA-seq data identiﬁed 773 (403 up, 370 down)
signiﬁcantly deregulated lncRNAs (Figure 1A, Online
Table 2). The analysis of RNA-seq data for protein-
coding genes of HUVECs cultured under normoxic or
hypoxic conditions showed 8,156 (4,032 up, 4,124
down) signiﬁcantly deregulated mRNAs (Figure 1B,
Online Table 2). The log2-fold expression changes
derived from the 2 different technologies were
signiﬁcantly correlated both for lncRNAs (Pearson
correlation coefﬁcient ¼ 0.43, p < 2.2  1016) and
for protein-coding genes (Pearson correlation
coefﬁcient ¼ 0.74, p < 2.2  1016) (Online Figure 1).
RNA-seq also conﬁrmed enhanced expression of
LINC00323 (lnc-DSCAM-1) under hypoxia (Online
Table 2).
In addition, from the RNA-seq data, we identiﬁed
another hypoxia-sensitive lncRNA, MIR503HG (lnc-
PLAC1-1), on the basis of the following criteria: 1)
minimal 4-fold up-regulation; 2) base mean >1,000;
and 3) intergenic annotation. On the basis of these
stringent criteria, we identiﬁed lnc-MST1P9-2 and
lnc-PLAC1-1 as high propriety candidates but omitted
lnc-MST1P9-2 from further studies because of poten-
tial protein-coding properties. Subsequent validation
experiments conﬁrmed the hypoxia-dependent
up-regulation of the previous 2 array- or RNA-
seq-derived lincRNAs, LINC00323 and MIR503HG
(Figure 1C and Online Figure 1 for other LINC00323
transcript isoforms). Cell compartment–speciﬁc RNA
analysis revealed hypoxia-dependent enhanced
cytoplasmic LINC00323-003 expression, whereas
MIR503HG was increased both in the nuclear and
cytoplasmic compartments (Figure 1C). High purity
of subcellular compartment preparations was proved
by screening expression of the nuclear enriched
lncRNA XIST (Online Figure 1). Endothelial up-
regulation of these 2 lncRNAs by hypoxia was
cell-type speciﬁc, as this was not seen in human
cardiac ﬁbroblasts or human aortic smooth muscle
cells exposed to hypoxia (Online Figure 1). The 2
lncRNAs were considerably expressed in ECs and
vascularized organs, such as kidneys (data notshown). We next sought to identify potential func-
tional relevance for the identiﬁed lncRNA candi-
dates in human ECs.
LINC00323-003 AND ANGIOGENIC FUNCTIONS.
LINC00323 is encoded on chromosome 21 and has 3
transcript isoforms (21,22) according to the lncRNA
database LNCipedia and the Ensembl Genome
Browser (Figure 2A). We focused on LINC00323 tran-
script variant 3, as a small interfering RNA (siRNA)
approach had obvious effects on EC biology to reduce
cell number in vitro. Next to proangiogenic hypoxic
signaling, endothelial VEGF treatment also increased
LINC00323-003 expression (Figure 2B). Multiple
in vitro assays were performed to clarify the func-
tional relevance of endothelial LINC00323-003
expression. Because LINC00323-003 was detectable
in nuclear and cytoplasmatic compartments, we used
both antisense-mediated siRNA (targeting cytoplasmic
lncRNAs) and GapmeR (targeting nuclear lncRNAs)
approaches in HUVECs. Both approaches in a trans-
genic LINC00323-003 overexpressing EC line docu-
mented potent lncRNA silencing (Online Figure 2).
Liposomal-based control GapmeR–ﬂuorescein trans-
fection in ECs led to an accumulation in the nucleus
(Online Figure 2). Titration experiments for the siRNA
chemistry showed detrimental effects on EC viability
in a range of 1 to 100 nmol/l siRNA, whereas appli-
cation of 100 pmol/l of siRNA exhibited no signiﬁcant
effect (Online Figure 2). Further siRNA experiments
were thus performed with 1 nmol/L of siRNA to
reduce potential off-target effects. Both siRNA- and
GapmeR-mediated LINC00323-003 silencing led to an
inhibition of human EC proliferation (Figure 2C,
Online Figure 2), suggesting cytoplasmic and nuclear
LINC00323-003 expression to be critical for endo-
thelial proliferation. In line, LINC00323-003 silencing
increased the ratio of binucleic to total cells and led to
an increase in EC size, suggesting proliferation de-
fects (Online Figures 2 and 3). Accordingly, the cell-
cycle inhibitors p21 and p27 were up-regulated,
whereas cell-cycle progression-relevant cyclin-
dependent kinases 1 and 2 were reduced upon endo-
thelial LINC00323-003 silencing (Figure 2D, Online
Figure 3). Migration capacity was also strongly atten-
uated by LINC00323-003 loss (Online Figure 3).
Angiogenic capacity tested by capillary tube forma-
tion assays was signiﬁcantly deteriorated upon
LINC00323-003 silencing (Figure 2E). This was paral-
leled by a repression of proangiogenic VEGFb and in-
duction of the angiogenesis inhibitor thrombospondin
(Online Figure 3). Loss of LINC00323-003 additionally
inhibited proliferation-important extracellular signal–
regulated kinase phosphorylation, and both led to a
FIGURE 1 RNA-Sequencing and Microarray Application to Identify Hypoxia-Sensitive Noncoding RNAs in HUVECs
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(A) Differentially expressed long noncoding ribonucleic acids (lncRNAs) are represented in this volcano plot of hypoxic versus normoxic human
umbilical vein endothelial cells (HUVECs) (fold change) from ribonucleic acid (RNA) sequencing analysis. MIR503HG/lnc-PLAC1-1 and
LINC00323/lnc-DSCAM-1 are marked with red arrows. The x-axis shows log2-transformed fold change; the y-axis shows adjusted p values
(Online Table 2). (B) Differentially expressed messenger RNAs (mRNAs) for coding genes are shown in a volcano plot of hypoxic versus
normoxic HUVECs from RNA sequencing. The x-axis shows log2-transformed fold change; the y-axis shows adjusted p values (Online Table 2).
(C) Long intergenic noncoding ribonucleic acids (lincRNAs) LINC00323-003 and MIR503HG in fractionated RNA (total, nuclear, and cyto-
plasmic) from HUVECs subjected to normoxia and hypoxia are validated. Fold change of normoxia (set to 1) is plotted. Qualitative polymerase
chain reaction analysis for LINC00323-003 applying DDCt-method, for MIR503HG applying standard curve analysis (n ¼ 3/4 experiments with
3 technical replicates). *p < 0.05; **p < 0.01; ***p < 0.001.
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2009repression of the key endothelial transcription factor
GATA2 and proangiogenic sirtuin I (Online Figure 3,
Figure 2F). Indeed, part of the detrimental actions
of LINC00323-003 were mediated through GATA2
silencing, as genetic overexpression of a functional
GATA2 construct attenuated the LINC00323-003
actions on ECs (Online Figure 3). Interestingly,
LINC00323-003 silencing reduced GATA2 protein but
not mRNA levels (Figure 2G), suggesting a post-
translational mechanism. Using starBase (23,24), a
bioinformatic-based identiﬁcation system, we found
potential protein candidates interacting with
LINC00323-003 that are also involved in mRNA
translation and identiﬁed the translation initia-
tion factor eIF4A3. Indeed, we were able to immu-
noprecipitate eIF4A3 in human ECs (Figure 2H).
RNA immunoprecipitation experiments in a stable
LINC00323-003-overexpression EC line revealed
signiﬁcant enrichment of LINC00323-003 with im-
munoprecipitated eIF4A3 compared with controls
(Figure 2I). In addition, GATA2 mRNA was found to be
associated with eIF4A3 (Figure 2J). This suggests a
scaffold function of LINC00323-003 to bind proteins,
such as the translation initiation factor eIF4A3
(Central Illustration). LINC00323-003 silencing also
caused impaired proliferative capacity of human cor-
onary artery ECs, suggesting a broad impact of this
lncRNA on various types of ECs (Online Figure 3).
ENDOTHELIAL FUNCTIONS OF HYPOXIA-SENSITIVE
lncRNA MIR503HG. The RNA-seq-derived lincRNA
MIR503HG is located at chromosome X, harbors a
coding sequence of miR-503, and is adjacent to miR-
424 (Figure 3A). Indeed, analysis of primary miR-503
and mature miR-503 expression after hypoxia
showed a similar increase of expression reﬂecting
same regulatory mechanisms for transcriptional acti-
vation (Figure 3B). However, both miR-503 and
lincRNA MIR503HG modulations had different effects
on EC function; whereas transfection of miR-503
precursors resulted in negative effects on EC
viability (Online Figure 4), knockdown of MIR503HG
suppressed endothelial proliferation independent
of alterations of apoptosis (Figures 3C and 3D,
Online Figure 4). MIR503HG silencing via GapmeR
technology led to reduced miR-503 expression
(Online Figure 4). In contrast, transfection of miR-503
precursors did not alter MIR503HG expression
(Online Figure 4), suggesting dependency of miR-
503 expression on MIR503HG but not vice versa.
Migratory capacity of MIR503HG-deﬁcient ECs was
additionally inhibited (Figure 3E). The proliferative
and migratory functional defects in ECs after
MIR503HG silencing were paralleled by a strongup-regulation of the cell-cycle inhibitor p21 (Online
Figure 4). In line with data from LINC00323-003
loss-of-function experiments, silencing of MIR503HG
repressed expression of the key angiogenic tran-
scription factor GATA2 (Figure 3F). Additionally, we
identiﬁed another miRNA, miR-424, genetically
neighboring upstream to MIR503HG. Surprisingly,
MIR503HG repression up-regulated neighboring miR-
424 expression (Figure 3G). Conclusively, this obser-
vation supports a cis-action of lnc-MIR503HG on
neighboring miR-424. MiR-424 was previously
described to be antiproliferative in lung arterial ECs;
moreover, its overexpression triggers antiangiogenic
effects in human ECs (25). Indeed, we were able to
validate these ﬁndings and found impaired prolifera-
tion of human ECs after miR-424 overexpression
(Figure 3H). However, no signiﬁcant effects toward
impairment of angiogenesis were observed when
analyzing capillary tube formation after MIR503HG
silencing (Online Figure 4). Intrinsic modulation in
arterial ECs had only minor effects on cellular
behavior, suggesting a different impact of MIR503HG
in venous and arterial ECs (Online Figure 4).
ENHANCED lincRNA EXPRESSION IMPROVES
MIGRATORY CAPACITY. To study the role of
enhanced lincRNA expression in ECs, the hypoxia-
sensitive lincRNAs LINC00323-003 and MIR503HG
were both overexpressed by generation of stable
green ﬂuorescent protein (GFP)-expressing EC lines
(Ea.Hy926) (Online Figure 5). Transgenic Ea.Hy926
constitutively overexpressing LINC00323-003 re-
vealed improved endothelial healing in the scratch
wound assay and showed enhanced cytoprotective
HMOX1 expression (Online Figure 5). In contrast, no
changes in endothelial biology were observed after
MIR503HG overexpression (Online Figure 5).
TRANSLATING IN VITRO CELL CULTURE FINDINGS
INTO A 3-DIMENSIONAL EX VIVO MODEL. To inves-
tigate whether the in vitro ﬁndings could be validated
in a 3-dimensional ex vivo model, we generated
human induced pluripotent stem cell–derived engi-
neered heart tissues (EHTs) enriched with GFP-
overexpressing HUVECs for easy identiﬁcation of
ECs in such human ex vivo constructs. HUVECs
showed 99% purity after blasticidine selection, as
conﬁrmed by ﬂow cytometric analysis (data not
shown) and GFP ﬂuorescence microscopy (Figure 4A).
EHTs were transfected with siRNA LINC00323-003,
GapmeR MIR503HG, or scrambled controls on days
5, 10, and 15 of culture, and analyses were performed
for EHT development and number of ECs. Dystrophin
staining of cross-sectioned EHTs showed a homoge-
nous distribution and high density of cardiomyocytes
FIGURE 2 Endothelial LINCRNA LINC00323-003 Expression Is Crucial for Endothelial Cellular Function
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CENTRAL ILLUSTRATION Vascular Importance of Angiogenic Long
Noncoding Ribonucleic Acids
GATA2
Translation via
       eIF4A3
miR-424
Vascularization
IncRNA Enchancement                   IncRNA Inhibition
IncRNA-based Therapy
LINC00323-003                                                    IncRNA MIR503HG
Fiedler, J. et al. J Am Coll Cardiol. 2015; 66(18):2005–15.
Summarizing scheme to emphasize vascular importance and therapeutic strategy to
modulate LINC00323-003 and MIR503HG expression to improve or to inhibit tissue
vascularization. Expression of the long noncoding ribonucleic acids (lncRNAs) LINC00323-
003 and MIR503HG is needed to sustain vascular homeostasis and endothelial cell biology;
lowering LINC00323-003 and MIR503HG triggers a cascade of antiangiogenic events via
repression of GATA2. In the case of LINC00323-003, interaction with eIF4A3 controls
GATA2 translation, while lncRNA MIR503HG controls neighboring miR-424 expression.
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2011(Figure 4B), which were similarly observed in all
groups (data not shown). Quantiﬁcation of GFP-
expressing HUVECs (Figures 4C to 4G) identiﬁed a
signiﬁcantly smaller number of ECs in LINC00323-003
and MIR503HG loss-of-function EHTs compared
with control tissue constructs. These data suggest
that silencing LINC00323-003 and MIR503HG, not
only in vitro but also in an ex vivo human EHT
model, impairs endothelial biology and tissue
vascularization.
DISCUSSION
Hypoxia is a strong proangiogenic stimulus and
induces VEGF-mediated signaling in ECs (19). The
present study provides evidence that lncRNA expres-
sion in ECs is strongly altered by hypoxia. We have
identiﬁed 2 novel lncRNAs, LINC00323-003 and
MIR503HG, that are highly sensitive to hypoxia and
crucial for endothelial angiogenic characteristics. The
mechanisms leading to the hypoxia-mediated regula-
tion of these lncRNAs remain to be determined. To this
end, we silenced HIF1a during hypoxic cell culture
of HUVECs and tested effects on LINC00323-003
and MIR503HG expression. Silencing HIF1a did not
abrogate hypoxia-mediated induction of lncRNAs
compared with controls (data not shown). This is sug-
gestive of HIF1a-independent mechanisms of the 2
hypoxia-induced lncRNAs described here and is in
line with the Encyclopedia of DNA Elements dataset
at the University of California, Santa Cruz, showing
no HIF1a-binding sites in promoter regions of
these lncRNAs. Importantly, silencing these lnc RNAs
impaired the function of ECs blocking proliferative
pathways. Both lncRNAs have never been described
in endothelial biology, but here we show that they
function as crucial factors to control EC behavior.
Key experiments for LINC00323-003 were also
validated in arterial ECs, suggesting the importance on
ECs in general. Of translational importance, lncRNA(A) Genomic localization of LINC00323-003, adapted from National Ce
thelial cells (HUVECs) treated with vascular endothelial growth factor (VE
ribonucleic acid (siRNA) transfection against LINC00323-003 decreases
immunosorbent assay (n ¼ 3 experiments). (D) The cell-cycle inhibitor p
Matrigel-based tube formation assay demonstrates less capillary formati
(F) GATA2 and sirtuin I (SIRT1) are reduced in siRNA LINC00323-003 tr
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FIGURE 4 Application of LINCRNA LINC00323-003 and MIR503HG Knockdown Strategy in Human EHT Is Detrimental for Vascularization
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(A) Green ﬂuorescent protein (GFP) ﬂuorescence of lentivirally transduced human umbilical vein endothelial cells (HUVECs). (B) Dystrophin
staining of cardiac myocytes in cross-sectioned EHT (brown staining of membranes). Scale bar ¼ 100 mm. In GFP staining of cross-sectioned
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2013MIR503HG was dependent on their high deregula-
tion in either microarray or RNA-seq datasets. It is
likely that many other thus far uncharacterized
lncRNAs also have crucial functions in endothelialbiology and should be investigated in future
studies; the database of array- and RNA-seq-based
lncRNA expression proﬁles reported here will be
helpful in this context.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Angiogenesis is a key mechanism by which organs
maintain blood supply, and this has therapeutic
implications for amelioration of ischemia in organs or
inhibition of vessel-dependent cancers. LncRNAs are
key regulators of endothelial proliferation and play a
role in angiogenesis.
TRANSLATIONAL OUTLOOK: Future research
should examine the potential role of interventions
that increase or normalize lncRNA expression and cell
type–speciﬁc function to modulate angiogenesis in
patients with myocardial infarction, peripheral arterial
disease, or ischemic stroke.
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2014STUDY LIMITATIONS. Both lncRNAs LINC00323-003
and MIR503HG exerted an important functional
relevance for EC biology, making them potential
attractive molecular targets in vascular diseases. We
have provided initial insight into their interaction
partners, such as miRNAs and proteins, but we wish
to point out that more in-depth mechanistic studies
are needed in the future to fully understand the mode
of action of the identiﬁed lncRNAs. In general,
lncRNAs are less (sequence) conserved among spe-
cies, thus hampering translational approaches in a
relevant in vivo vascular disease setting in other
species models. To circumvent this limitation, we
applied a model of human induced pluripotent stem
cell–based EHT to translate the importance of these 2
lncRNAs in endothelial biology in a more realistic
translational scenario.
CONCLUSIONS
We have identiﬁed 2 novel hypoxia-sensitive endo-
thelial lncRNAs, LINC00323-003 and MIR503HG, by
the use of microarray and next-generation RNA-seq
techniques. Functional characterization applying
loss- and gain-of-function approaches in cultured
ECs revealed an important role for both of these
lncRNAs in endothelial biology. Our data enable the
future development of novel lncRNA-therapeutic
approaches to cardiovascular diseases. More general,
our data identify novel strategies based on lncRNA
modulation to alter tissue vascularization, with the
aim of either enhancing (e.g., in ischemic tissues)
or blocking (e.g., in vessel-dependent cancers)
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